Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-12-15

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In a certified lung- cancer center, patients with NSCLC and a potentially curative stage (including patients with oligometastatic disease) are prospectively enrolled if curative treatment (either definitive radio-chemotherapy or resection) cannot be performed due to large tumor size or for functional reasons. For these patients, the multidisciplinary tumor board (MDB) recommends immuno-(chemo)therapy and re-evaluation. Response is assessed radiologically including PET-CT if indicated. After review of the MDB, patients receive either definitive curative treatment or palliative treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

NCT04465942

Carcinoma, Non-Small-Cell Lung Immunotherapy

UNKNOWN

Atezolizumab Immunotherapy in Patients With Advanced NSCLC

NCT03102242

Carcinoma, Non-Small-Cell Lung

COMPLETED PHASE2

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients

NCT04205552

NSCLC Stage II NSCLC, Stage IIIA NSCLC, Stage I

RECRUITING PHASE2

Neoadjuvant Immunotherapy in Advanced NSCLC

NCT05137912

Lung Cancer, Non-small Cell

UNKNOWN

GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT00509457

Carcinoma, Non-Small-Cell Lung

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In a certified lung- cancer center, patients with NSCLC and a potentially curative stage (including patients with oligometastatic disease) are prospectively enrolled if curative treatment (either definitive radio-chemotherapy or resection) cannot be performed due to large tumor size or for functional reasons (e. g. too large radiation field or functionally inoperable for the required resection). For these patients, the multidisciplinary tumor board (MDB) recommends immuno-(chemo)therapy and re-evaluation. Response is assessed radiologically including PET-CT if indicated. After review of the MDB, patients receive either definitive curative treatment or palliative treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Non-Small-Cell Lung

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

induction therapy

induction immuno-chemotherapy or immunotherapy prior to resection or definitive chemoradiotherapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* newly diagnosed NSCLC
* histologically or cytologically proven
* stage III - IVA (oligometastatic) by complete staging
* ECOG 0-2
* life expectancy 3 months
* ability to provide written informed consent